Stay updated with breaking news from John Climaco. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Live video webcast with Chief Executive Officer, John Climaco, on Tuesday, April 23rd at 12:00 PM ETHOUSTON, TX / ACCESSWIRE / April 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...
Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin study enrollment completed; Topline data expected in first half of 2025Clinical progress represents important steps towa...
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights ...
01.04.2024 - Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin study enrollment completed; Topline data expected in ... Seite 1
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially ...